Quince Therapeutics gets USPTO notice of allowance in Ataxia-Telangiectasia

Quince Therapeutics (QNCX) “announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 17/083,771 entitled Process for the Preparation of Erythrocytes Loaded With One or More Substances of Pharmaceutical Interest and So Obtained Erythrocytes. The newly allowed application covers the method of treating patients with Ataxia-Telangiectasia and provides patent coverage for preparing erythrocytes loaded with one or more substances of pharmaceutical interest using the EryDex process. The first independent claim of this application is not limited to any particular pharmaceutical product and is broader than currently granted parent patent claims. Supplementing the company’s existing U.S. Patent No. 10,849,858, Quince now has issued patents directed to the process for encapsulating erythrocytes with a therapeutic drug as well as a method of treating a patient with encapsulated erythrocytes.